Canadian Cancer Society announces inaugural Impact Grants
HAMILTON, ON, Feb. 26, 2013 /CNW/ - A new type of radiation therapy
could potentially change the standard of care for people with
inoperable early-stage lung cancer.
The Canadian Cancer Society has awarded a $1.2 million Impact Grant to
Dr Anand Swaminath, a radiation oncologist at Juravinski Cancer Centre,
to lead a Canadian clinical trial comparing two different types of
radiation therapy for lung cancer.
Stereotactic radiation uses advanced imaging techniques to deliver
extremely precise high doses of radiation in fewer treatments, while
conventional radiation delivers lower doses in more frequent
treatments. The effectiveness of these two radiation therapies in
treating lung cancers has never been compared in a large clinical
The clinical trial will look at the effectiveness of each type of
radiation in shrinking tumours as well as overall survival, severity of
side effects and quality of life for patients.
"If stereotactic radiation is found to be more effective than
conventional therapy, with fewer side effects and lower healthcare
costs, this type of radiation could become the standard of care for
inoperable early-stage lung cancer across Canada and internationally,"
says Dr Swaminath, Assistant Professor, Department of Oncology,
"Significant funding such as the Society's Impact Grant provides us the
time and resources needed to determine the effectiveness of this
therapy and possibly lead to better care for a hard-to-treat cancer,"
"We are thrilled to be able to fund these outstanding new research
projects that have such tremendous promise," says Luba Slatkovska,
Senior Manager, Research, Canadian Cancer Society. "In our 75th
anniversary year, we remain committed to making a difference in the
lives of Canadians by funding the best research and making the most
impact against cancer."
Dr. Swaminath's grant is one of 11 new Impact Grants awarded today by
the Canadian Cancer Society for a total value of more than $13 million.
This new funding program is designed to provide a mechanism for
scientists to adopt innovations and accelerate the application of new
knowledge to address problems in cancer research. These grants have the
potential to improve patient quality of life and reduce cancer
incidence and deaths.
These are the largest single grants ever offered by the Canadian Cancer
Society at a maximum value of $1.25 million per grant over five years.
They are highly prestigious grants and are intended to fund the best,
most promising cancer science in the country and move it significantly
For 75 years, the Canadian Cancer Society has been with Canadians in the
fight for life. We have been relentless in our commitment to prevent
cancer, fund research and support Canadians touched by cancer. From
this foundation, we will work with Canadians to change cancer forever
so fewer Canadians are diagnosed with the disease and more survive.
When you want to know more about cancer, visit our website at cancer.ca or call our toll-free bilingual Cancer Information Service at
1-888-939-3333 (TTY: 1-866-786-3934).
SOURCE: Canadian Cancer Society (Ontario Division)
For further information:
Senior Coordinator, Public Affairs
Canadian Cancer Society, Ontario Division